Electrochemotherapy for the Treatment of Human Sarcoma in Athymic Rats

Electrochemotherapy is the combined use of a chemotherapeutic agent and pulsed electric fields. Electrical treatment causes an increase in cell membrane permeability which allows the chemotherapeutic agent to more freely enter the tumor cells. Electrochemotherapy has been under development in clinical trials. This study focused on determining the applicability of electrochemotherapy for treating soft tissue sarcoma using an animal model bearing human sarcomas. The antitumor effects of several concentrations of cisplatin, bleomycin, doxorubicin, and netropsin as single agents delivered with electric pulses were investigated based on post-treatment tumor volumes and histology. Electrochemotherapy treatment resulted in 5% to 88.9% durable complete responses; ECT that employed bleomycin resulted in the highest antitumor effects. This indicates the feasibility of electrochemotherapy as a modality for limb preserving treatments for sarcoma of the extremities.

Download Full-text

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s0424820100072460 ◽

1973 ◽

Vol 31 ◽

pp. 404-405

Author(s):

D. C. Swartzendruber ◽

Norma L. Idoyaga-Vargas

Keyword(s):

Clinical Trials ◽

Soft Tissue ◽

Tumor Tissue ◽

Soft Tissue Tumors ◽

Clinical Usefulness ◽

Electron Microscopic ◽

Normal Cells ◽

Electron Microscopic Autoradiography ◽

Peritoneal Cells ◽

Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Download Full-text

A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent

Journal of the Royal Statistical Society Series C (Applied Statistics) ◽

10.1111/rssc.12508 ◽

2021 ◽

Author(s):

Beibei Guo ◽

Elizabeth Garrett‐Mayer ◽

Suyu Liu

Keyword(s):

Clinical Trials ◽

Phase I ◽

Chemotherapeutic Agent ◽

Cancer Clinical Trials ◽

Immunotherapeutic Agent

Download Full-text

The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy

Cancers ◽

10.3390/cancers13153865 ◽

2021 ◽

Vol 13 (15) ◽

pp. 3865

Author(s):

Tânia Fortes-Andrade ◽

Jani Sofia Almeida ◽

Luana Madalena Sousa ◽

Manuel Santos-Rosa ◽

Paulo Freitas-Tavares ◽

...

Keyword(s):

Clinical Trials ◽

Soft Tissue ◽

Nk Cells ◽

Nk Cell ◽

Malignant Tumors ◽

Soft Tissue Sarcomas ◽

Good Prognosis ◽

Regulatory Pathways ◽

Immunological Profile ◽

Study Support

Soft-tissue sarcomas (STS) represent about 80% of sarcomas, and are a heterogeneous group of rare and malignant tumors. STS arise from mesenchymal tissues and can grow into structures such as adipose tissue, muscles, nervous tissue and blood vessels. Morphological evaluation has been the standard model for the diagnosis of sarcomas, and even in samples with similar characteristics, they present a diversity in cytogenetic and genetic sequence alterations, which further increases the diversity of sarcomas. This variety is one of the main challenges for the classification and understanding of STS patterns, as well as for their respective treatments, which further decreases patient survival (<5 years). Despite some studies, little is known about the immunological profile of STS. As for the immunological profile of STS in relation to NK cells, there is also a shortage of studies. Observations made in solid tumors show that the infiltration of NK cells in tumors is associated with a good prognosis of the disease. Notwithstanding the scarcity of studies to characterize NK cells, their receptors, and ligands in STS, it is noteworthy that the progression of these malignancies is associated with altered NK phenotypes. Despite the scarcity of information on the function of NK cells, their phenotypes and their regulatory pathways in STS, the findings of this study support the additional need to explore NK cell-based immunotherapy in STS further. Some clinical trials, very tentatively, are already underway. STS clinical trials are still the basis for adoptive NK-cell and cytokine-based therapy.

Download Full-text

Contributions from surgeons to clinical trials and research on the management of soft tissue sarcoma

Annals of Surgical Oncology ◽

10.1007/bf02303862 ◽

1998 ◽

Vol 5 (5) ◽

pp. 437-441 ◽

Cited By ~ 8

Author(s):

Peter J. Allen ◽

Alexander Stojadinovic ◽

Craig D. Shriver ◽

David P. Jaques

Keyword(s):

Clinical Trials ◽

Soft Tissue ◽

Soft Tissue Sarcoma

Download Full-text

COVID-19: Are Experimental Drugs Cure or Ill?

Current Drug Safety ◽

10.2174/1574886316666210727150127 ◽

2021 ◽

Vol 16 ◽

Author(s):

Bensu Karahalil ◽

Aylin Elkama

Keyword(s):

Clinical Trials ◽

Severe Acute Respiratory Syndrome ◽

Adverse Effects ◽

Antiviral Treatment ◽

Herd Immunity ◽

Mortality Rates ◽

Death Rates ◽

Experimental Drugs ◽

Combined Use ◽

The World

Background: Coronavirus disease 2019 (COVID-19) is a new strain of coronavirus. It is characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has quickly influenced all over the world since it spreads easily. Common symptoms are fever, cough, difficulty in breathing and muscle aches. Despite the urgent need to find an effective antiviral treatment, already available agents are being used alone or in combination all over the world. At the beginning of the pandemic, death rates of infection caused by COVID-19 are high but "is COVID-19 responsible for all deaths?", or “are there any contributions of the frequently used drugs in this period to these deaths?” Surely herd immunity plays a major role and has the contribution in the decline in mortality rates. Meanwhile, it is kept in mind that due to safety concerns, changes have also been made to the dosage and combined use of frequently used drugs. Objective: In this review, answers to two questions above and the safety of treatments, toxicities of agents involving chloroquine, hydroxychloroquine, remdesivir, favipiravir, lopiravir/ritonavir, sarilumab, tocilizumab, siltuximab, corticosteroids and bromhexine which are the most frequently used in both Turkey and all over the world will be summarized. Conclusion: Among these drugs favipiravir seems the most promising drug due to more tolerable adverse effects. More clinical trials with large sample sizes are needed to find the most effective and safe drug for COVID-19 treatment.

Download Full-text

Combined use of ultrasonic cavitation and vacuum therapy in compiex treatments of acute puruient-necrotic processes

Bukovinian Medical Herald ◽

10.24061/2413-0737.xviii.4.72.2014.237 ◽

2014 ◽

Vol 18 (4 (72)) ◽

Author(s):

I. V. Shkvarkovkyi ◽

T. V. Antoniuk

Keyword(s):

Wound Healing ◽

Soft Tissue ◽

Ultrasonic Cavitation ◽

New Method ◽

Vacuum Therapy ◽

Combined Use

A new method for the treatment of patients with acute purulent necrotic processes by means of ultrasonic cavitation and vacuum therapy has been elaborated. The aim was to study the combined influence of ultrasonic cavitation and vacuum therapy on the course of wound healing. The method complements the treatment of patients with severe purulent necrotic processes of soft tissue.

Download Full-text

Sex differences in the antithrombotic effects of aspirin

Blood ◽

10.1182/blood.v52.5.1073.1073 ◽

1978 ◽

Vol 52 (5) ◽

pp. 1073-1076 ◽

Cited By ~ 55

Author(s):

JG Kelton ◽

J Hirsh ◽

CJ Carter ◽

MR Buchanan

Keyword(s):

Clinical Trials ◽

Animal Model ◽

Arterial Thrombosis ◽

Sodium Salicylate ◽

Inhibitory Effect ◽

Prostaglandin Synthesis ◽

Antithrombotic Effect ◽

Antithrombotic Agent ◽

Male And Female ◽

Antithrombotic Effects

Abstract Aspirin inhibits platelet function by acetylating platelet cyclooxygenase. Recent clinical trials indicate that aspirin is a promising antithrombotic agent against both venous and arterial thrombosis, but somewhat surprisingly this protective effect appears to be limited to males. To examine the potential sex-related differences in response to aspirin, we developed an animal model for quantitating fibrin accretion into an injury-induced thrombus and used it to study the effects of aspirin on thrombus size in male and female rabbits. Platelet prostaglandin synthesis was estimated by assay of platelet malondialdehyde and was significantly decreased in both male and female rabbits following treatment with 10 mg/kg aspirin (p less than 0.001). This inhibitory effect was not different for platelets from male and female rabbits. Thrombus size was significantly decreased in aspirin- treated male rabbits when compared to controls (p less than 0.05), but this aspirin effect was not apparent in female rabbits or rabbits of either sex treated with 10 mg/kg sodium salicylate. These findings support the results of clinical trials that were obtained by retrospective subgroup analysis. The reason for the sex difference is not known, but the findings raise an important issue in relationship to this mechanism of the antithrombotic effect of aspirin.

Download Full-text

Review of the clinical trials activity of the soft tissue and bone sarcoma group of the european organization for research and treatment of cancer

Seminars in Surgical Oncology ◽

10.1002/ssu.2980040110 ◽

1988 ◽

Vol 4 (1) ◽

pp. 45-52 ◽

Cited By ~ 3

Author(s):

Vivien H. C. Bramwell ◽

A. Santoro ◽

J. Rouesse ◽

H. Mouridsen ◽

W. Steward ◽

...

Keyword(s):

Clinical Trials ◽

Soft Tissue ◽

Bone Sarcoma ◽

European Organization

Download Full-text

Rotator Cuff Tendinosis in an Animal Model: The Role of Extrinsic and Overuse Factors

10.1115/imece2000-2557 ◽

2000 ◽

Author(s):

S. Thomopoulos ◽

A. Esmail ◽

J. D. Williamson ◽

C. L. Flanagan ◽

J. P. Iannotti ◽

...

Keyword(s):

Animal Model ◽

Soft Tissue ◽

Rotator Cuff ◽

Musculoskeletal System ◽

Soft Tissue Injuries ◽

Rotator Cuff Disease ◽

Extrinsic Compression ◽

In Vivo Animal Model

Abstract One of the most common soft tissue injuries of the musculoskeletal system is injury to the rotator cuff tendons of the shoulder. These injuries are commonly attributed to factors such as overuse activity and extrinsic compression. Previous studies on the rotator cuff have been based on surgical reconstructive or clinical retrospective standpoints and were not designed to test hypotheses related to the causes of rotator cuff tendinosis. Our previous study has identified the rat as an appropriate in vivo animal model in which to study rotator cuff disease based on anatomic and functional similarities [1]. The current study uses this animal model to study the roles of extrinsic compression, overuse, and overuse combined with extrinsic compression, on the development of rotator cuff tendinosis. It was hypothesized that a single injury factor would be insufficient to create persistent tendinosis and a combination of injury factors would be necessary.

Download Full-text